The primary endpoint of 12-month Event Free Survival (EFS) for OST-HER2- treated patients (33.3%) was statistically significant (p= 0.0158) when compared with peer-reviewed comparable historical...
The primary endpoint of 12-month Event Free Survival (EFS) for OST-HER2- treated patients (33.3%) was statistically significant (p= 0.0158) when compared with peer-reviewed comparable historical...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.7 | -14 | 5 | 5.4999 | 4 | 42963 | 4.70490536 | CS |
4 | -0.21 | -4.65631929047 | 4.51 | 5.93 | 3.53 | 65218 | 4.43000679 | CS |
12 | 1.3 | 43.3333333333 | 3 | 6.48 | 1.58 | 64037 | 3.74436604 | CS |
26 | 0.3 | 7.5 | 4 | 6.48 | 1.58 | 120163 | 3.75366052 | CS |
52 | 0.3 | 7.5 | 4 | 6.48 | 1.58 | 120163 | 3.75366052 | CS |
156 | 0.3 | 7.5 | 4 | 6.48 | 1.58 | 120163 | 3.75366052 | CS |
260 | 0.3 | 7.5 | 4 | 6.48 | 1.58 | 120163 | 3.75366052 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.